Bullous systemic lupus erythematosus (BSLE ... and up to 90% will develop kidney disease in their lifetime. Anywhere from 40% to 90% of people with BSLE experience anemia, leukopenia, or both.

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

Dermatomyositis and lupus may share symptoms in some cases. Here's what you need to know about these autoimmune conditions.

Incurable Autoimmune Disease Systemic Lupus Erythematosus (SLE): New Genetic Findings Open Up Perspectives for Future Therapeutic Approaches Jan. 14, 2024 — Systemic lupus erythematosus (SLE ...

A NEW Swedish study has found that menopausal hormone therapy (MHT) may be associated with an increased risk of developing ...

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with a strong female predilection. Cardiovascular morbidity and mortality is a frequent complication, particularly in females ...

EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...

Patients with cutaneous lupus were 1.72 times more likely to have cardiovascular disease than matched ... 24,675 patients with systemic lupus erythematosus (SLE), 192,577 with psoriasis and ...

Topical mupirocin helps reduce inflammation in lupus, offering a potential new approach for managing symptoms and improving ...

Increased odds of atherosclerotic cardiovascular disease seen in association with cutaneous lupus and systemic lupus, but not psoriasis. HealthDay News — Cutaneous lupus erythematosus (CLE ...

Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus ... for cardiac events and kidney disease progression vs.